Dr. Reddy's Laboratories Limited (RDDA) - Total Assets
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) holds total assets worth €562.90 Billion EUR (≈ $658.09 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dr. Reddy's Laboratories Limited - Total Assets Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's total assets have evolved over time, based on quarterly financial data. Also see RDDA stock market capitalisation for the company's overall valuation and market capitalisation.
Dr. Reddy's Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Dr. Reddy's Laboratories Limited's total assets of €562.90 Billion consist of 50.7% current assets and 49.3% non-current assets. Review how much debt does Dr. Reddy's Laboratories Limited carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 3.0% |
| Accounts Receivable | €90.42 Billion | 18.3% |
| Inventory | €71.08 Billion | 14.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €96.80 Billion | 19.6% |
| Goodwill | €11.81 Billion | 2.4% |
Asset Composition Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See RDDA live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dr. Reddy's Laboratories Limited's current assets represent 50.7% of total assets in 2025, an increase from 45.7% in 2017.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, up from 1.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, unchanged from 21.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 19.6% of total assets.
Dr. Reddy's Laboratories Limited Competitors by Total Assets
Key competitors of Dr. Reddy's Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Dr. Reddy's Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.88 | 1.92 | 1.78 |
| Quick Ratio | 1.38 | 1.37 | 1.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €139.24 Billion | €121.07 Billion | €64.86 Billion |
Dr. Reddy's Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Dr. Reddy's Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.79 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 27.2% |
| Total Assets | €492.99 Billion |
| Market Capitalization | $9.23 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Dr. Reddy's Laboratories Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dr. Reddy's Laboratories Limited's assets grew by 27.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual total assets of Dr. Reddy's Laboratories Limited from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €492.99 Billion ≈ $576.36 Billion |
+27.22% |
| 2024-03-31 | €387.52 Billion ≈ $453.05 Billion |
+20.03% |
| 2023-03-31 | €322.85 Billion ≈ $377.45 Billion |
+8.83% |
| 2022-03-31 | €296.65 Billion ≈ $346.82 Billion |
+11.74% |
| 2021-03-31 | €265.49 Billion ≈ $310.39 Billion |
+14.32% |
| 2020-03-31 | €232.24 Billion ≈ $271.51 Billion |
+3.02% |
| 2019-03-31 | €225.43 Billion ≈ $263.55 Billion |
-0.08% |
| 2018-03-31 | €225.60 Billion ≈ $263.75 Billion |
+2.63% |
| 2017-03-31 | €219.82 Billion ≈ $256.99 Billion |
-- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more